Fingerprint
Dive into the research topics of 'LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
Toni K. Choueiri, Thomas Powles, Martin H. Voss, Elizabeth R. Plimack, Howard Gurney, Yue Song, Rodolfo F. Perini, Karla Rodriguez-Lopez, Brian I. Rini
Research output: Contribution to journal › Article › peer-review
75
Downloads
(Pure)